Trial Profile
CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy: a multi-center, prospective, two-arm, open label, non inferiority phase II study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms CABACARE
- 24 Dec 2022 The trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 16 Feb 2019 A total of 35 Italian centers have started / will start recruiting pts in the CABACARE trial and 43 pts have been enrolled since 30th Nov , 2017 until 2nd Oct, 2018 in 10 different Italian Institutions, as per trial design presented at the 2019 Genitourinary Cancers Symposium.
- 16 Oct 2017 New trial record